Draft scientific and technical guidance for the preparation and presentation of an application for authorisation of an infant and/or follow-on formula manufactured from protein hydrolysates

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), Dominique Turck, Jean-Louis Bresson, Barbara Burlingame, Tara Dean, Susan Fairweather-Tait, Marina Heinonen, Karen Ildico Hirsch-Ernst, Inge Mangelsdorf, Harry J McArdle, Androniki Naska, Monika Neuhäuser-Berthold, Grażyna Nowicka, Kristina Pentieva, Yolanda Sanz, Anders Sjödin, Martin Stern, Daniel Tomé, Henk Van Loveren, Marco Vinceti, Peter Willatts, Mary Fewtrell, Hildegard Przyrembel

Abstract

Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to provide scientific and technical guidance for the preparation and presentation of applications for authorisation of infant and/or follow-on formula manufactured from protein hydrolysates. This guidance document addresses the information and data to be submitted to EFSA on infant and follow-on formulae manufactured from protein hydrolysates with respect to the safety and suitability of the specific formula and/or the formula’s efficacy in reducing the risk of developing allergy to milk proteins. The guidance will be further reviewed and updated with the experience gained from the evaluation of specific applications for authorisation, and in the light of future Community guidelines and legislation. The NDA Panel endorsed this guidance on 13 December 2016 for public consultation, to which stakeholders are encouraged to contribute. The document will be revised and updated according to the comments received, where appropriate.

Keywords: protein hydrolysates, infant formula, follow-on-formula, application, guidance, food allergy, milk proteins

Requestor: European Commission
Question number: EFSA-Q-2016-00276
Correspondence: nda@efsa.europa.eu
Panel members: Jean-Louis Bresson, Barbara Burlingame, Tara Dean, Susan Fairweather-Tait, Marina Heinonen, Karen Ildico Hirsch-Ernst, Inge Mangelsdorf, Harry J McArdle, Androniki Naska, Monika Neuhäuser-Berthold, Grażyna Nowicka, Kristina Pentieva, Yolanda Sanz, Alfonso Siani, Anders Sjödin, Martin Stern, Daniel Tomé, Dominique Turck, Henk Van Loveren, Marco Vinceti and Peter Willatts

Acknowledgements: The Panel wishes to thank the members of the Working Group on Infant Nutrition: Jean-Louis Bresson; Mary Fewtrell, Hildegard Przyrembel, Dominique Turck, and the hearing experts: Rosangela Marchelli and Daniel Tomé for the preparatory work on this scientific output, and EFSA staff members: Ariane Titz and Silvia Valtueña Martínez for the support provided to this scientific output.


ISSN: 1831-4732

© 2017 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf of European Food Safety Authority.

This is an open access article under the terms of the Creative Commons Attribution-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited and no modifications or adaptations are made.

The EFSA Journal is a publication of the European Food Safety Authority, an agency of the European Union.
Summary
A summary will be provided after the public consultation.
# Table of contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abstract</td>
<td>1</td>
</tr>
<tr>
<td>Summary</td>
<td>3</td>
</tr>
<tr>
<td>Background as provided by the European Commission</td>
<td>5</td>
</tr>
<tr>
<td>Terms of reference as provided by the European Commission</td>
<td>5</td>
</tr>
<tr>
<td>Scope</td>
<td>6</td>
</tr>
<tr>
<td>Objectives</td>
<td>6</td>
</tr>
<tr>
<td>General principles</td>
<td>6</td>
</tr>
<tr>
<td>Organisation and content of the application</td>
<td>8</td>
</tr>
<tr>
<td>1. Part 1: Administrative and technical data</td>
<td>8</td>
</tr>
<tr>
<td>1.1. Comprehensive table of contents of the dossier</td>
<td>8</td>
</tr>
<tr>
<td>1.2. Identification form</td>
<td>8</td>
</tr>
<tr>
<td>1.3. Party responsible for the dossier</td>
<td>8</td>
</tr>
<tr>
<td>1.4. Nature of the application</td>
<td>8</td>
</tr>
<tr>
<td>2. Part 2: Characterisation of the formula</td>
<td>9</td>
</tr>
<tr>
<td>2.1. Name and characteristics of the formula</td>
<td>9</td>
</tr>
<tr>
<td>2.2. Manufacturing process of the formula</td>
<td>10</td>
</tr>
<tr>
<td>2.3. Characteristics of the protein hydrolysate</td>
<td>10</td>
</tr>
<tr>
<td>2.4. Manufacturing process of the protein hydrolysate</td>
<td>10</td>
</tr>
<tr>
<td>2.5. Stability information</td>
<td>10</td>
</tr>
<tr>
<td>2.6. References</td>
<td>11</td>
</tr>
<tr>
<td>3. Part 3: Nutritional safety and suitability of the hydrolysed formula</td>
<td>11</td>
</tr>
<tr>
<td>3.1. Rationale for the use of the specific protein hydrolysate in the formula and the expected nutritional benefits</td>
<td>11</td>
</tr>
<tr>
<td>3.2. Pre-clinical data</td>
<td>11</td>
</tr>
<tr>
<td>3.3. Clinical data</td>
<td>11</td>
</tr>
<tr>
<td>3.3.1. Published clinical studies not proprietary to the applicant</td>
<td>14</td>
</tr>
<tr>
<td>3.3.2. Clinical studies unpublished and/or proprietary to the applicant</td>
<td>14</td>
</tr>
<tr>
<td>4. Part 4: Efficacy of the formula in reducing the risk of developing allergy to milk proteins</td>
<td>14</td>
</tr>
<tr>
<td>4.1. Rationale for the use of the specific protein hydrolysate in the formula and the expected reduction in the risk of developing allergy to milk proteins</td>
<td>14</td>
</tr>
<tr>
<td>4.2. Pre-clinical data</td>
<td>14</td>
</tr>
<tr>
<td>4.3. Clinical data</td>
<td>14</td>
</tr>
<tr>
<td>4.3.1. Published clinical studies not proprietary to the applicant</td>
<td>16</td>
</tr>
<tr>
<td>4.3.2. Clinical studies unpublished and/or proprietary to the applicant</td>
<td>16</td>
</tr>
<tr>
<td>5. Part 5: Copies and reprints</td>
<td>16</td>
</tr>
<tr>
<td>5.1. Copies/reprints of pertinent published studies/articles not proprietary to the applicant</td>
<td>16</td>
</tr>
<tr>
<td>5.2. Copies and reprints of protocols and full study reports of clinical studies unpublished and/or proprietary to the applicant</td>
<td>17</td>
</tr>
<tr>
<td>References</td>
<td>17</td>
</tr>
<tr>
<td>Abbreviations</td>
<td>18</td>
</tr>
<tr>
<td>Appendix A – Identification form</td>
<td>19</td>
</tr>
<tr>
<td>Appendix B – Information to be presented in a full study report for clinical studies unpublished and/or proprietary to the applicant</td>
<td>20</td>
</tr>
</tbody>
</table>
**Background as provided by the European Commission**

Commission Directive 2006/141/EC\(^1\) lays down requirements for infant formulae and follow-on formulae placed on the market in the EU. The Directive allows the use of protein hydrolysates as source of protein in infant formulae and follow-on formulae under certain conditions (Articles 5-7; Annex I, point 2.2; Annex II, point 2.2 and Annex VI). The Directive also lays down conditions for infant formulae manufactured from protein hydrolysates to bear a health claim describing the role of such products in reducing the risk of developing allergy to milk proteins (Article 13(6) and Annex IV, point 2.1).

Commission delegated Regulation (EU) 2016/127\(^2\) repeals Directive 2006/141/EC and revises the rules applicable to infant formula and follow-on formula, taking account of the opinion of the European Food Safety Authority (EFSA) of 2014 (EFSA, 2014a).

In that opinion, EFSA noted that "the safety and suitability of each specific formula containing protein hydrolysates has to be established by clinical studies. Information on protein sources and the technological processes applied should also be provided. In this context, the Panel notes that one particular formula containing partially hydrolysed whey protein has been evaluated for its safety and suitability by the Panel [ (...)] and has been authorised for use by Directive 2006/141/EC". EFSA also noted that "the criteria given in Directive 2006/141/EC alone are not sufficient to predict the potential of a formula to reduce the risk of developing allergy to milk proteins. Clinical studies are necessary to demonstrate if and to what extent a particular formula reduces the risk of developing short- and long-term clinical manifestations of allergy in at-risk infants who are not exclusively breast fed".

In light of the above, Commission delegated Regulation (EU) 2016/127 establishes that infant formula and follow-on formula manufactured from protein hydrolysates should only be allowed to be placed on the market if their composition corresponds to the one already positively assessed by EFSA and prohibits the use of health claims describing the role of infant formula manufactured from protein hydrolysates in reducing the risk of developing allergy to milk proteins.

As explained in the Regulation's recitals, these requirements may be amended in the future in order to allow the placing on the market of formulae manufactured from protein hydrolysates with a composition different from the one already positively assessed, following a case-by-case evaluation of their safety and suitability by EFSA. In addition, if, after the assessment by EFSA, it is demonstrated that a specific formula manufactured from protein hydrolysates reduces the risk of developing allergy to milk proteins, further consideration will be given to how to adequately inform parents and caregivers about that property of the product.

The requirements of Commission delegated Regulation (EU) 2016/127 shall apply to infant formula and follow-on formula manufactured from protein hydrolysates from 2021. The Commission expects that, before that date, dossiers on formulae manufactured from protein hydrolysates will be presented by food business operators for assessment by EFSA with a view to request possible modifications to the conditions applicable to these products in the delegated Regulation.

In this context, it is considered necessary to consult EFSA regarding the type of data that food business operators should make available to the Authority in the future, when submitting such dossiers on formulae manufactured from protein hydrolysates.

**Terms of reference as provided by the European Commission**

In accordance with Article 29 of Regulation (EC) No 178/2002\(^3\), the European Commission requests the European Food Safety Authority to issue an opinion on scientific and technical guidance regarding

---


the type of data that will be considered appropriate by EFSA for providing scientific advice to the Commission on infant formulae and follow-on formulae manufactured from protein hydrolysates and, in particular, on:

1) the safety and suitability of a specific formula manufactured from protein hydrolysates and,

2) the product’s efficacy in reducing the risk of developing allergy to milk proteins.

In preparing this scientific and technical guidance, EFSA is requested to take into account the requirements laid down in Regulation (EU) No 609/2013 and delegated Regulation (EU) 2016/127 and its opinion of 2014 on the essential composition of infant and follow-on formulae.

Scope

This guidance document addresses the information and data to be submitted to EFSA in relation to applications for authorisation of infant formulae (IF) and/or follow-on formulae (FOF) manufactured from protein hydrolysates. It covers applications for the assessment of the safety and suitability of the formula and applications on the product's efficacy in reducing the risk of developing allergy to milk proteins.

Objectives

The guidance presented in this document is intended to assist applicants in the preparation and presentation of well-structured applications for authorisation of IF and/or FOF manufactured from protein hydrolysates and for assessing the product’s efficacy in reducing the risk of developing allergy to milk proteins.

It presents a common format for the organisation of the information to be provided and outlines:

- the information and scientific data which must be included in the application
- the key issues which should be addressed in the application to substantiate the safety and suitability of the formula and/or its efficacy in reducing the risk of developing allergy to milk proteins.

It is intended that the guidance will be kept under review, and will be further amended and updated as appropriate in the light of the experience gained in subsequent evaluations.

General principles

1) In the context of this guidance:

   Infant means a child under the age of 12 months;

   Infant formula (IF) means food intended for use by infants during the first months of life and satisfying by itself the nutritional requirements of such infants until the introduction of appropriate complementary feeding;

   Follow-on formula (FOF) means food intended for use by infants when appropriate complementary feeding is introduced and which constitutes the principal liquid element in a progressively diversified diet of such infants;

   Hydrolysed formula means an IF or a FOF manufactured from a protein hydrolysate;

   Control formula means a formula that is used in clinical studies as comparator and meets the requirements laid down in Regulation (EU) No 609/2013 and delegated Regulation (EU) 2016/127

---

2) This guidance presents a common format for the organisation of the information in order to assist the applicant in the preparation of a well-structured application. Adherence to this format will also facilitate easy access to information and scientific data in applications to help the NDA Panel to carry out its evaluation and to deliver its scientific advice in an effective and consistent way.

3) It is the duty of the applicant to provide all available scientific data (including data in favour and not in favour) which are pertinent to the application. In its evaluation, the Scientific Panel on Dietetic Products, Nutrition and Allergies (NDA Panel) may use data which are not included in the application if they are considered pertinent to the claim. However, the NDA Panel should not be required to undertake any additional literature reviews, or to assemble or process data in order to evaluate the application. As such, the application should be comprehensive and complete. Each application will be considered on a case-by-case basis.

4) The application must contain information on the characteristics of the formula for which the application is made. This information should contain aspects such as the composition, physical and chemical characteristics, manufacturing process and stability. Measurements should be performed in a competent laboratory which can certify the data. Whenever a quality system is in place for performance/control/documentation (e.g. good manufacturing practice (GMP), good laboratory practice (GLP), applicable ISO standard), the particular system should be indicated.

5) In order to substantiate the safety and suitability of a formula manufactured from protein hydrolysates, at least one human intervention study on outcomes of growth in the target population for which the formula is intended (i.e. healthy infants in the general population) should be provided.

6) In order to substantiate the efficacy of a product in reducing the risk of developing allergy to milk proteins, at least one human intervention study on the incidence of allergy to milk proteins in the target population for which the formula is intended (i.e. infants at risk of developing allergic diseases) should be provided.

7) Non-human data could be submitted as part of the overall pertinent scientific evidence, but are not sufficient to substantiate the safety and suitability of an IF and/or FOF or to establish the efficacy of a product in reducing the risk of developing allergy to milk proteins.

8) The entire application cannot be claimed as confidential. Specific parts, sections, words, graphs or datasets considered as confidential by the applicant should be kept to a minimum and should be clearly identified. The applicant is required to provide detailed and verifiable justification for every part of the dossier claimed as confidential.

9) EFSA will make public, once adopted, its scientific opinion on the data and information included in the application, excluding the information considered as confidential. In order to comply with its requirements for transparency as outlined in Article 38 of Regulation (EC) No 178/2002, EFSA has to disclose in its published scientific opinions data from dossiers which are considered essential for the scientific assessment. To this end, EFSA will take a decision on the confidentiality claims submitted by the applicant. For example, confidentiality can only be given to specific parts of an unpublished study report if duly justified, and not to the entire study. If the request for confidential treatment for those parts identified by the applicant is accompanied by verifiable justification\(^5\), and if this is accepted by EFSA, those elements will be processed by EFSA in a confidential manner, and will not be disclosed in the published version of the final scientific opinion. EFSA’s decisions on confidentiality are communicated to applicants before the scientific opinion is adopted.

10) One application should be prepared for each hydrolysed formula. If the proposed modification in terms of proteins is the same for both IF and FOF, they may be addressed in the same application.

\(^5\) Precise and factual information, ideally documents, proving that disclosure of the information requested by the applicant to be treated as confidential would result in concrete harm to the commercial or economic interest of the applicant/requestor, or would undermine the protection of privacy and the integrity of concerned individual(s).
This document should be read in conjunction with Regulation (EU) No 609/2013 and delegated Regulation (EU) 2016/127, and future guidelines and regulations, as applicable.

**Organisation and content of the application**

The following information should be provided in the application and the structure should follow a common format. Data provided in the application should be organised into five Parts:

**Part 1** contains administrative and technical data, such as the identification form, and information related to the party responsible for the dossier, to confidential information contained in the dossier, and to the national and international regulatory status.

**Part 2** contains information relative to the characterisation of the hydrolysed IF and/or FOF, including its name and characteristics, list of ingredients, its energy and nutrient content, a description of the manufacturing process, and stability information.

**Part 3** contains information about the nutritional safety and suitability of the formula, including a comprehensive review of the scientific evidence and a summary of pertinent growth studies performed in the target population.

**Part 4**, where applicable, contains information related to the product’s efficacy in reducing the risk of developing allergy to milk proteins. It includes a comprehensive review of the scientific evidence and a summary of pertinent studies in populations at risk of developing allergic diseases.

**Part 5** contains the reprints of the references and the study reports identified as being pertinent for the assessment.

Where some of the data described in this guidance do not apply to a particular dossier, reasons/justification must be given for the absence of such data in the dossier.

1. **Part 1: Administrative and technical data**

1.1. **Comprehensive table of contents of the dossier**

Please provide a table of contents of the dossier.

1.2. **Identification form**

Please use the identification form provided in Appendix A.

1.3. **Party responsible for the dossier**

**Company/organisation**

Please provide the name and address of the company or organisation.

**Contact person**

Please indicate the contact person authorised to communicate with EFSA on behalf of the party responsible for the dossier.

1.4. **Nature of the application**

Please indicate whether the application relates to:

---

6 In case more than one company or organisation submits dossier, provide their names and addresses. Only one contact person is authorised to communicate with EFSA.

7 To facilitate communication, only one contact person should be indicated per dossier.
☐ an IF

Please explain in which way the formula does not comply with the specifications laid down in Regulation (EU) 2016/127, where appropriate.

☐ a FOF

Please explain in which way the formula does not comply with the specifications laid down in Regulation (EU) 2016/127, where appropriate.

☐ the efficacy of an IF and/or a FOF in reducing the risk of developing allergy to milk proteins.

Confidential data

State whether the dossier includes confidential data: ☐ yes ☐ no

If yes, please specify the related Part in the dossier, stating section and page number, and providing verifiable justification(s)/declaration(s) (see also general principle 8 of this guidance document).

<table>
<thead>
<tr>
<th>Elements of the application dossier for which a request for confidentiality treatment was filed by the applicant</th>
<th>Section(s) or data sets, and page number(s)</th>
<th>Verifiable justification(s)/reason(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Please also highlight the sections in the dossier you consider confidential in another font colour.

National and international regulatory status

Please state whether the formula has been marketed within or outside the European Union. If so, provide information about the countries, areas or regions in which the formula is marketed and about the duration for which the product has been available on the market.

Please indicate whether the formula or its efficacy in reducing the risk of developing allergy to milk proteins has been scientifically evaluated by an authoritative or scientific body, either within or outside the European Union. If so, provide a copy of the scientific evaluation in Part 5.

2. Part 2: Characterisation of the formula

2.1. Name and characteristics of the formula

Please provide the specifications of the formula (e.g. physical and chemical properties, composition, and, where applicable, microbiological constituents), the list of ingredients and their sources, as well as the energy and nutrient content of the formula as consumed. The quantities should be given per 100 mL ready-made formula and per 100 kcal. Please specify the methodology used to assess the energy and nutrient content of the specific product. Batch-to-batch variability of the formula should also be addressed.

---

If analytical methods are applied to provide a quantitative analysis of the energy and nutrient content, please provide information on the measures in place to ensure the quality and consistency of the data. Please also indicate whether the measurements have been performed in a competent facility that can certify the data. Whenever a quality system is in place for control/documentation (e.g. GLP and ISO17025), the particular system should be indicated.

2.2. Manufacturing process of the formula

Please provide a description of the manufacturing process of the formula. This should also contain information about the addition of free amino acids, vitamins, minerals, fats, carbohydrates, and other substances. If the production follows a quality system (e.g. GMP), the particular system should be indicated. If the manufacturing process is claimed as confidential, a non-confidential summary of the manufacturing process should also be provided in the dossier for transparency reasons.

2.3. Characteristics of the protein hydrolysate

Starting material

Please provide information on the protein source which is the basis of the hydrolysed protein and on whether a single protein or a mixture of proteins is used. Individual intact proteins (used as such or in mixtures for the preparation of the protein hydrolysate) should be identified by their molecular weight.

Protein hydrolysate

Information on the degree of hydrolysis of the protein, the molecular weight distribution of peptides and residual proteins, the amount of residual protein and of free amino acids, the overall amino acid pattern, the nitrogen content, the non-amino nitrogen content (including the ratio of total to non-amino nitrogen), and the nature of non-protein nitrogen, should be provided.

The hydrolysed protein should also be characterised by molecular peptide fingerprinting for identification purposes. The method used for fingerprinting should be described.

Information should also be provided on the batch-to-batch variability in relation to the parameters described above.

2.4. Manufacturing process of the protein hydrolysate

A detailed description of the procedure used to isolate the starting material, as well as of the manufacturing process of the protein hydrolysate, should be provided. The hydrolytic conditions (e.g. enzymatic/chemical hydrolysis, pH, temperature, duration (hours)) used to produce the hydrolysate should be outlined. Information on degradation products (type and amount) formed during the manufacturing process of the hydrolysate should also be provided.

If the production follows a quality system (e.g. GMP), the particular system should be indicated. If the manufacturing process is claimed as confidential, a non-confidential summary of the manufacturing process should also be provided in the dossier for transparency reasons.

2.5. Stability information

A brief summary of the studies undertaken (e.g. conditions, batches and analytical procedures), and of the results and conclusions of the stability studies, should be provided. Conclusions with respect to storage conditions and shelf-life should be given.
2.6. References

References and supporting documentation quoted under Part 2 should be given here (including authors, title and publication year, no particular format required), together with copies/reprints of published data and/or full reports of unpublished data.

3. Part 3: Nutritional safety and suitability of the hydrolysed formula

3.1. Rationale for the use of the specific protein hydrolysate in the formula and the expected nutritional benefits

A rationale for the use of the specific protein hydrolysate in a formula should be provided, together with an indication of the nutritional benefits that could be expected from the use of the hydrolysate in the formula and a rationale/evidence why such nutritional benefits could be expected.

3.2. Pre-clinical data

Information on in vitro or in vivo studies in animal models or other experimental settings should be provided if they may help to establish the nutritional adequacy, potential nutritional benefits, and/or the safety of the proposed formula (SCF, 2003).

3.3. Clinical data

In order to demonstrate the safety and suitability of the formula manufactured from hydrolysed protein, at least one adequately powered clinical study in the target population is required. Guidance on the expected characteristics of such study is provided below.

Study objectives

The objectives of the study should be to assess the effects of the formula manufactured from protein hydrolysate (hydrolysed formula) on measures of growth as compared to accepted growth standards and to a formula manufactured from intact protein or from protein hydrolysates complying with the compositional requirements laid down in Regulation (EU) No 609/2013 and delegated Regulation (EU) 2016/127 (control formula).

Study products

Evidence should be provided that the hydrolysed IF and/or FOF used in the study complies with the specifications provided in Section 2.2 with respect to the characterisation of the formula manufactured from hydrolysed protein that is the subject of the application.

Evidence should also be provided that the IF and/or FOF control formula used in the study complies with the compositional requirements laid down in Regulation (EU) No 609/2013 and delegated Regulation (EU) 2016/127.

Study design

At least one randomised, parallel study on the effects of the hydrolysed formula on measures of growth as compared to both the control formula and accepted growth standards is required. The inclusion in the study of a breast-fed reference group is not required.

If the objective of the study is to detect similarity in growth between the hydrolysed and the control formula, the study should be designed and analysed as an equivalence study using a pre-defined margin of equivalence/non-inferiority. The Panel notes that different equivalence/non-inferiority
margins have been suggested for use in infant growth studies\(^9\). Therefore, it is important to pre-
define (at the protocol phase) the equivalence/non-inferiority margin used to power the study and to
provide a rationale why such margin has been considered as appropriate for that purpose.

The design of the study (in particular with respect to randomisation, allocation of subjects to groups,
blinding, and sample size calculation) should be in line with generally accepted scientific principles.

In studies assessing the safety and suitability of hydrolysed IF, the intervention with the study
formulas (hydrolysed and control) as the only source of nutrition should last at least three months.
Studies assessing the safety and suitability of hydrolysed FOF should cover at least three months after
complementary food is introduced.

**Study group**

The study group should be representative of the target population for which the hydrolysed formula is
intended, which is healthy term infants in the general population.

**Main outcome variables**

The study should be adequately powered to test the effects of the hydrolysed formula as compared to
the control formula on the following measures of growth:

1. Body weight (g)
2. Body length (mm)
3. Head circumference (mm)

These variables should be measured with a sufficient frequency during the study to establish the
growth pattern of infants, ideally every four weeks, and provided as absolute values, as changes from
baseline, and as the variable-for age z-scores at each assessment time point and for each study
group, together with an indication of the growth standard used to calculate z-scores and the reasons
for that choice.

Other outcome variables that should be assessed at different time points throughout the study
include:

4. IF and/or FOF intake, together with information on the methods used to ascertain formula
   intake.
5. Intake of complementary foods, where appropriate, together with information on the methods
   used to ascertain food intake.
6. Tolerance of the study products and adverse events

Information on changes in laboratory values may provide additional information in certain
circumstances, but it is not essential for assessing the safety and suitability of a formula manufactured
from protein hydrolysates with respect to growth patterns.

**Basic dataset**

All infants included in the clinical trials should be well characterised, especially with regard to factors
that might affect the planned outcomes. In order to allow a comprehensive scientific assessment of
the study, the following information\(^10\) should be provided:

- Infant sex
- Parity
- Delivery conditions (vaginal, C-section)
- Birth weight in grams
- Gestation in completed weeks
- Birth weight for gestation (z-score for sex and gestation)
- Date of birth

---

\(^9\) E.g. 0.5 z-score difference (SCF, 2003), 3 g/day difference in weight gain over a 3 to 4 month period (AAP, 1988).

\(^{10}\) Modified from Aggett et al. (2003)
• Number of live born infants from the pregnancy
• Age at recruitment into the study
• Age at randomisation
• Age at baseline (i.e. at the start of the intervention)
• Anthropometry at baseline (in absolute values and z-scores, together with an indication of the growth standard used to calculate z-scores)
  o Body length
  o Body weight
  o Head circumference
• Date of, and age at, each assessment time point
• Anthropometry at each assessment time point (in absolute values and z-scores)
  o Body length
  o Body weight
  o Head circumference
• Feeding history
  o Whether breast or formula-fed
  o Duration of exclusive human milk feeding
  o Duration of partial human milk feeding
  o Duration of exclusive formula feeding
  o Type(s) of formula used
• Maternal age and education
• Date and age when stopped participating as per protocol
• Reason/s for non-compliance
• Age at withdrawal from the study
• Reason/s for withdrawal from the study
• Advice given to parents with respect to the complementary feeding period, where relevant
• Age of introduction of complementary food, where relevant
• Amount of complementary feeding expressed in E% at each assessment time point, where relevant
• Information about infections
• Adverse events

It is acknowledged that, for studies for which the protocol was finalised before adoption of the present guidance, information may not be available for all the items indicated. As a minimum, information should be provided on: infant sex, birth weight in grams, gestation in completed weeks, age at baseline, anthropometry at baseline, date and age at each assessment time point, anthropometry at each assessment time point, feeding history, age at and reasons for withdrawal.

**Statistical analysis**

The statistical analysis should be in line with generally accepted scientific principles.

Results should be provided for comparisons between the intervention and control groups for all outcome variables assessed. Growth patterns of the study groups should also be compared with accepted growth standards.

In particular, the following information should be provided:

1. Descriptive and inferential statistics for each assessment time point for both the intention-to-treat (ITT)\(^{11}\) (or the Full Analysis Set (FAS)\(^{12}\)) and the per protocol (PP)\(^{13}\) analyses;
2. The number of infants analysed at each time point for each analysis;
3. The point estimate and the associated confidence interval for continuous outcome variables;
4. The covariates used in the analysis, with appropriate justification for their use;
5. The results of both the adjusted and the unadjusted analysis;

\(^{11}\) All infants randomised
\(^{12}\) All infants which were fed at least once with the study products
\(^{13}\) All infants which completed the protocol as planned
6. Reasons for drop-outs or withdrawal of infants from the study by the investigators, together with an assessment/discussion of the impact of drop-outs/withdrawals on the study results.

Reporting

In case of studies proprietary to the applicant, applications should include the study protocol and the full study report in line with the information requested in Appendix B of this guidance.

3.3.1. Published clinical studies not proprietary to the applicant

Published clinical studies on the safety and suitability of the formula manufactured from hydrolysed protein which are not proprietary to the applicant should be identified in a systematic and transparent manner through a comprehensive review of the scientific literature\(^{14}\). A reference list and a brief summary of the studies identified through the comprehensive review of the scientific literature should be given here.

Copies/reprints of pertinent published studies/articles not proprietary to the applicant should be provided in Part 5.

3.3.2. Clinical studies unpublished and/or proprietary to the applicant

A reference list and a summary of the studies (published or unpublished) on the safety and suitability of the formula manufactured from hydrolysed protein, which are proprietary to the applicant, should be given here.

The study protocol and the full study report of studies which are proprietary to the applicant should be provided in Part 5.

4. Part 4: Efficacy of the formula in reducing the risk of developing allergy to milk proteins

4.1. Rationale for the use of the specific protein hydrolysate in the formula and the expected reduction in the risk of developing allergy to milk proteins

A rationale for the use of the specific protein hydrolysate in the formula should be provided, together with a rationale/evidence why reduction in the risk of developing allergy to milk proteins in the target population could be expected.

4.2. Pre-clinical data

Information on in vitro or in vivo studies in animal models or other experimental settings should be provided if they may help to establish the potential of the hydrolysed formula to reduce the risk of developing allergy to milk proteins.

4.3. Clinical data

In order to demonstrate the efficacy of a formula manufactured from hydrolysed protein in reducing the risk of developing allergy to milk proteins (e.g. cow's milk allergy, goat's milk allergy), at least one adequately powered and designed clinical study is required. Guidance on the expected characteristics of these studies is provided below.

\(^{14}\) Applicants could consider the EFSA guidance on the application of systematic review methodology to food and feed safety assessments to support decision making for that purpose (EFSA, 2010).
Draft Guidance for applications on infant and follow-on formula from protein hydrolysates

Study objectives

The objectives of the study should be to assess the effects of the hydrolysed formula on the incidence of allergy to milk proteins as compared to a control formula manufactured from intact protein from the same source as the hydrolysate and complying with the compositional requirements laid down in Regulation (EU) No 609/2013 and delegated Regulation (EU) 2016/127.

Study products

Evidence should be provided that the hydrolysed IF and/or FOF tested in the study complies with the specifications provided in Section 2.2 with respect to the characterisation of the formula manufactured from hydrolysed protein that is the subject of the application.

Evidence should also be provided that the IF and/or FOF control formula used in the study complies with the compositional requirements for formula manufactured from intact protein laid down in Regulation (EU) 2016/127, and that the IF and/or FOF control formula has been manufactured from the same source as the hydrolysed formula that is the subject of the application.

Study design

At least one randomised, parallel study on the effects of the hydrolysed formula on the incidence of allergy to milk proteins as compared to the control formula is required.

The study should be designed as a superiority study in line with generally accepted scientific principles (in particular with respect to randomisation, allocation of subjects to groups, blinding, and sample size calculation).

Infants could be enrolled at any time from birth and prior to the introduction of milk proteins other than breast milk. The efficacy of hydrolysed IF and FOF on reducing the risk of developing allergy to milk proteins could be tested in the same study (e.g. hydrolysed IF given before the introduction of complementary feeding; hydrolysed FOF given at the time of introduction of complementary feeding and thereafter).

The Panel cannot set specific requirements with respect to the duration of the intervention and/or the duration of the follow-up. However, the Panel considers that reducing the risk of developing allergy to milk proteins during, at least, the first year of life would be clinically significant for the target population. Claims on the reduction of the risk of allergic disease for longer periods of time would require longer follow-ups.

Since factors other than the use of (hydrolysed or control) formula may affect the development of food allergy, including the development of allergic reactions to milk proteins (e.g. breast feeding and mother’s diet, age of introduction of complementary foods, socioeconomic factors; EFSA, 2014b), care should be taken that such factors are taken into consideration in the study design.

Study group

The study group should be representative of the target population for which the hydrolysed formula is intended. Hydrolysed IF and FOF intended to reduce the risk of developing allergy to milk proteins should be tested in healthy term infants at risk of developing allergic diseases (e.g. having at least one parent or one sibling with ascertained allergic/atopic disease). Care should be taken to exclude from enrolment infants with established allergy to milk proteins.

Main outcome variables

The study should be adequately powered to test the effects of the hydrolysed formula as compared to the control formula on the risk of developing allergy to milk proteins. In this context, allergic symptoms occurring during the study (intervention and/or follow-up) should be documented using validated clinical scoring systems. Allergy to milk proteins should be confirmed using double-blind placebo-controlled food challenges (DBPCFC). Open-label food challenges controlled and evaluated by a physician may be sufficient for the confirmation of food allergy in infants and young children ≤ 3 years old under certain circumstances (Bindslev-Jensen et al., 2004; Sampson et al., 2012).

Allergen-specific serum IgE antibodies denote sensitisation to a particular food, but they do not provide information about the occurrence or the severity of allergic reactions following oral exposure.
Draft Guidance for applications on infant and follow-on formula from protein hydrolysates

573 to that food, since individuals with significant allergen-specific IgE levels may not experience any
574 clinical symptoms when challenged with that allergen (EFSA, 2014b).

575 In cases of suspected IgE-mediated immunological reactions to food, a skin prick test (SPT) may be
576 performed. The diagnostic accuracy and sensitivity of an SPT in suspected food allergies varies
577 according to the possible offending food and is slightly higher than measuring allergen-specific IgE. A
578 positive SPT indicates sensitisation to the tested food, but it is not diagnostic of food allergy. Negative
579 reactions have a 95 % predictive value to exclude IgE-mediated reactions. However, positive tests
580 have only a 50 to 60 % positive predictive value (EFSA, 2014b).

581 Guidelines for the diagnosis of food allergy and consensus papers aiming for the standardisation of
582 oral challenge protocols have been published in Europe (Bindslev-Jensen et al., 2004; Muraro et al.,
583 2014) and the USA (Sampson et al., 2012).

584 Items highlighted in Section 3.3 (basic dataset) should also be considered in this section, where
585 applicable.

586 Statistical analysis

587 The statistical analysis should be in line with generally accepted scientific principles (see also Section
588 3.3. Statistical analysis).

589 Reporting

590 In case of studies proprietary to the applicant, applications should include the study protocol and the
591 full study report in line with the information requested in Appendix B of this guidance.

592 Published clinical studies not proprietary to the applicant

593 Published clinical studies assessing the effects of the hydrolysed formula on the incidence of allergy to
594 milk proteins which are not proprietary to the applicant should be identified in a systematic and
595 transparent manner through a comprehensive review of the scientific literature\textsuperscript{15}. A reference list and
596 a brief summary of the studies identified through the comprehensive review of the scientific literature
597 should be given here.

598 Copies/reprints of pertinent published studies/articles not proprietary to the applicant should be
599 provided in Part 5.

600 Clinical studies unpublished and/or proprietary to the applicant

601 A reference list and a summary of the studies (published or unpublished) assessing the effects of the
602 hydrolysed formula on the incidence of allergy to milk proteins, which are unpublished and/or
603 proprietary to the applicant, should be given here.

604 The study protocol and the full study report of studies which are proprietary to the applicant should
605 be provided in Part 5.

5. Part 5: Copies and reprints

5.1. Copies/reprints of pertinent published studies/articles not proprietary to the applicant

\textsuperscript{15} Applicants could consider the EFSA guidance on the application of systematic review methodology to food and feed safety
assessments to support decision making for that purpose (EFSA, 2010).
5.2. Copies and reprints of protocols and full study reports of clinical studies unpublished and/or proprietary to the applicant

References


**Abbreviations**

- **AAP** American Academy of Pediatrics
- **DBPCFC** Double-blind placebo-controlled food challenge
- **EC** European Commission
- **EFSA** European Food Safety Authority
- **EU** European Union
- **FAS** Full Analysis Set
- **FOF** Follow-on formula
- **GLP** Good Laboratory Practice
- **GMP** Good manufacturing practice
- **IF** Infant formula
- **IgE** Immunoglobulin class E
- **ISO** International Organization for Standardization
- **ITT** Intention to treat analysis
- **NDA** Dietetic Products, Nutrition and Allergies
- **PP** per protocol analysis
- **SCF** Scientific Committee on Food
- **SPT** Skin prick test
Appendix A – Identification form

IDENTIFICATION FORM

The identification form should be used for a dossier on a specific food product for a scientific evaluation by the European Food Safety Authority (EFSA) in the context of Regulation (EU) 2016/127.

DECLARATION and SIGNATURE

Name of the specific food product:

Nature of the request:

Party responsible for the dossier (Company) name:
Address:
Country:

Contact person’s name:
Address:
Country:
Telephone:
e-mail:

It is hereby confirmed, to the best of our knowledge, that all existing data which are relevant to the dossier have been supplied, as appropriate.

On behalf of the applicant:

Signature
Name
Function
Place and date (dd-mm-yyyy)

16 To facilitate communication, only one contact person should be indicated per dossier.
Appendix B – Information to be presented in a full study report for clinical studies unpublished and/or proprietary to the applicant

A study report can be considered complete when it contains at least the information outlined in this guideline. This Appendix has been adapted from the International Conference on Harmonisation (ICH) guideline E3 on the structure and content of clinical study reports for the purpose of this guidance. Study reports which follow the full structure of ICH E3 are also acceptable.

Study reports not complying with the requirements outlined below may not allow a scientific evaluation of the study by the NDA Panel.

1. Title page
The title page should include information on hydrolysed IF and/or FOF under investigation, the primary outcome variable(s) studied, the method(s) used to assess the outcome variable(s), the study design (e.g. double or single-blind, two or more arms, single or multi-centre), the study group, the study initiation and completion dates, the place in which the study was conducted, the name of the sponsor, the funding source and its exact role and contribution to the study (e.g. in the design, conduct, analysis and/or reporting of the study, if any), the name of the principal investigator, the name of the author of the report, and the date when the report was signed off.

2. Summary

3. Table of contents

4. List of abbreviations and definition of terms

5. Ethical considerations
This should include information about the review and approval of the study by an ethics committee. Information about the ethical conduct of the study, and about how the informed consent was obtained from participants, should be provided.

6. Trial registration
It should be specified whether the study was registered in a trial registry. If so, the trial registration number should be given. In case the study was not registered, explanation should be given.

7. General information about the study
In this section, the name/affiliation of the investigators and other people with a major role in the study (e.g. staff carrying out observations related to the outcome variable(s) under investigation), the statisticians and the authors of the report, should be provided. The section should also include information about the facilities which were used (e.g. for multicentre studies: information about the study sites and about the use of a central laboratory vs. non-central sample analyses), and on whether a contract research organisation has been tasked to carry out the work.

8. Study objectives
The objective(s) of the study and the hypothesis to be tested should be specified in this section.

9. Study design
This section should outline whether the study was planned e.g. as open-label, single-blind (specifying who was blinded) or double-blind study, as a single- or multi-centre study (with a specification about the number of study sites). Information about the country setting, the type of control used (and the reasons why it was considered appropriate in the context of the study), the study duration and a discussion on the choice of the study design for investigating the selected outcome(s) should also be provided. In case the study was planned with an adaptive design, it should be specified which kind of adaptations at which time points were planned in the protocol and whether a Data Monitoring Committee was involved in the implementation of the plan.

10. Study group
The inclusion and exclusion criteria should be described, including the diagnostic criteria (and their validation) used to select subjects, if applicable. The appropriateness of the study group for the particular purpose of the study should be discussed. Any pre-defined criteria for excluding subjects from the study after randomisation should also be given, together with information on how these subjects were intended to be followed-up.

11. Study products
A detailed description of the hydrolysed IF and/or FOF under investigation and of the control formula, including information on the mode of administration and the amounts used, should be provided.

12. Method of assigning subjects to groups
Details on the method used to assign subjects to the study groups (randomisation or minimisation) should be given. It should be specified whether this allocation was done in a centralised or decentralised way, whether it was stratified (and if so by which factors) or whether the allocation was done in blocks. Information on the measures taken to conceal the allocation should also be described here.

13. Blinding
Information on the strategy used to ensure blinding should be provided, e.g. measures taken to ensure that the study products were not distinguishable by smell, taste or packaging; information on how products were labelled (e.g. by subject individual codes or other). Information should be given on who had access to the product codes, whether there were any pre-defined circumstances in which the blinding could be broken, and who from the team of investigators would be unblinded in case of such a need. If proper blinding could not be achieved, please discuss and justify why this was not possible. For studies with an adaptive design, it should be reported how it was ensured that the study personnel remained blinded to the interventions, especially if the pre-planned adaptation required unblinding of the data. In such a case, it should be justified why the particular adaptation made it necessary to unblind the data, and why the same aim could not have been achieved with statistical methods not requiring such unblinding.

14. Concomitant medication or interventions
Any concomitant medication or non-pharmacological intervention allowed by the study protocol should be described here.

15. Compliance with the intervention and the protocol
This section should include a detailed description of the measures taken to ensure and assess compliance with the intervention and the protocol.

16. Outcome variable(s) measured
Information about the pre-defined primary outcome variable(s), secondary outcome variable(s) and all other outcomes planned to be measured should be presented in this section. The methods used to assess the outcome variable(s) should be specified. This section should also include information about the timing of the measurements (e.g. flow-chart), and a justification of the appropriateness of the outcome variables chosen to achieve the objective(s) of the study.

17. Data quality assurance
Any measures taken with respect to the quality assurance of the data collected should be addressed here.

18. Pre-planned statistical analyses
This section refers to the statistical analysis planned before the implementation of the study, and should specify whether any sub-group analyses were pre-planned. The choice of each statistical technique should be appropriately justified. The data analysis sets (e.g. ITT, FAS, PP) should also be defined. It should be specified which of the analyses presented have been pre-specified as the main analysis in case several alternative analyses for one outcome are planned (e.g. ITT vs. PP or different models used). The reasons for the choice of the analysis should be given. If imputation of missing
data is foreseen, information should be given on how it is planned to assess the robustness of the assumptions made with respect to the imputation of data. For studies for which an adjustment for multiple comparisons is needed in order to preserve the family-wise type I error rate, the pre-planned approach towards adjusting for multiplicity should be specified. In case of studies with an adaptive design, the number and time-points of pre-specified interim analyses, as well as the statistical methods used to conserve the type I error rate, should be given. The appropriateness of the statistical method used for the design of the study should be discussed. Finally, it should be stated which analyses were planned to be confirmatory and which ones exploratory.

19. Determination of sample size

Detailed information on how the planned sample size of the study was calculated should be given here. This should include information about the expected size of the effect, the assumed standard deviation of the population, the significance level chosen, the anticipated power of the study, and the statistical tests (to be performed) to which the sample size calculation relates. In addition, information should be given on whether equal or unequal allocation to groups has been accounted for in the sample size calculation (if unequal allocation is foreseen) and whether any allowance for drop-out has been made. Finally, the programme used to calculate the sample size should be identified. In case of studies with adaptive design allowing for sample size re-estimation, the planned method for re-estimating sample size should be described.

20. Protocol amendments, deviations and violations/deviations from the planned approaches and analyses

Non-adherence or changes made during or after the study with respect to the pre-planned approaches or pre-planned analyses should be specified here.

Any protocol amendments (i.e. a systematic change in the protocol after approval), protocol deviations and violations (i.e. unplanned unsystematic deviations from the protocol with either minor effects (deviations) or affecting the scientific integrity (violations)) should be outlined.

A protocol amendment may, for example, relate to a systematic change of the pre-established inclusion and exclusion criteria, the planned study design, addition or deletion of endpoints, sample size, the planned statistical approaches or the definition of data analysis sets (e.g. ITT vs. PP). If no protocol amendments have been made, it should be confirmed that the study was carried out according to the protocol.

Protocol deviations and violations may relate, for example, to inadequate or not-timely collected informed consent, inclusion of subjects not meeting the eligibility criteria, improper breaking of the blind, improper assessment of an outcome, incorrect or missing tests, rescheduled or missed study visits, visits outside the permitted window, inadequate record keeping, use of not permitted medication or a non-pharmacological intervention.

Any additional exploratory analyses conducted which were not part of the (amended) protocol (e.g. unplanned sub-group analyses to inform a subsequent study) should also be recorded.

21. Subject flow

A clear description of the number of subjects screened, the number of subjects recruited, the number of subjects randomised, the number of subjects who entered and completed each study phase, the number of drop-outs and the number of withdrawals should be specified. The reasons for subjects dropping-out of the study or for having been withdrawn from the study by the investigators should be stated. Information about whether and when the blind was broken (if so) should also be given here.

22. Data sets analysed

This section should include a clear definition of each analysis set used for final analysis (e.g. ITT, FAS, PP), including information on the number of subjects available for each analysis at each assessment time point. In case PP analyses are presented, information should be given on the extent to which the subjects included in this analysis set could have deviated from the protocol, and the reasons why they were still eligible for inclusion in the PP analysis set. Finally, the reasons for excluding subjects from each analysis at each time point should be given.
23. Baseline characteristics of the study group
In this section, baseline characteristics for all analysis sets should be given (e.g. ITT, FAS, PP, completers, other) - overall and by study centre for multi-centre studies.

24. Results of assessment of compliance with the intervention and the protocol
Results of the assessment of compliance with the intervention and with the protocol should be given here.

25. Statistical analysis carried out
A detailed description of the statistical analysis carried out should be provided, in line with EFSA’s guidance on statistical reporting\(^\text{18}\). This description should include, amongst other, information on:

- the statistical programme used (version number and operating system),
- the type of statistical tests/models used,
- the test/model selection,
- the appropriateness of the test/model used for the type of data generated
- the handling of missing data (including a detailed description of the potential mechanism for missing data and of how the missing data were handled). If missing data was imputed, please described the methods used to do so and specify which sensitivity analyses were carried out, if any,
- the variables or factors used as fixed or as random effects (if appropriate),
- the assumed covariance structure for longitudinal analyses,
- the adjustment for covariates (and justification about the covariates used),
- the handling of data stemming from multicentre trials,
- whether any issue with respect to multiple comparisons arises (in case of multiple primary outcomes or multiple group comparisons, or if a secondary outcome is intended to be used as the primary efficacy criterion instead of the primary outcome); this should include a description of the method chosen for adjusting the analysis for multiple comparisons and information on the number of outcomes for which the analysis has been adjusted.

26. Results of the study
Results for all the outcome variables assessed and for all analysis sets investigated should be presented. The results should be given as estimates with associated confidence intervals and p-values (if corrected for multiple comparisons, both the uncorrected and corrected results (confidence intervals and p-values accounting for multiple comparisons) should be given). Results should be presented for all groups under investigation and for each assessment time point if foreseen in the pre-specified analysis plan; otherwise descriptive statistics should be included. The information should be presented in a tabular format, and not only graphically. For multi-centre trials, results or descriptive statistics for the individual centres should be presented (if pre-specified). The number of subjects included in each analysis and assessment time point should be provided. In case of data imputation, the results of the related sensitivity analyses should be included. The full outputs of the statistical analyses, together with the associated codes used for programming, should be given as an Annex. A full list of the abbreviations used to denominate variables or factors in the programming should also be given, so that the statistical outputs are self-explanatory.

27. Adverse events
Adverse events should be clearly reported (possibly indicating those which may be related to the intervention and those which may not be related to the intervention), together with information on the (diagnostic) criteria used to ascertain them.\(^\text{19}\)


\(^{19}\) For reporting of safety-related data see also ICH-E3-‘Structure and content of study reports’.